Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biden’s CUREIT initiative aims to develop a toolbox of technologies to fight cancer, autoimmune disorders and infectious diseases.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
Social media posts that make misleading comparisons undermine the science behind the COVID-19 vaccine.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.